Smith Kristine A, Smith Timothy L, Mace Jess C, Rudmik Luke
Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, University of Calgary, Calgary, AB, Canada.
Int Forum Allergy Rhinol. 2014 Oct;4(10):823-7. doi: 10.1002/alr.21366. Epub 2014 Sep 11.
The decision to continue medical therapy or recommend endoscopic sinus surgery (ESS) can be challenging in patients with refractory chronic rhinosinusitis (CRS). The objective of this study was to evaluate continued medical therapy vs ESS for patients with refractory CRS who have severe reductions in baseline disease-specific quality of life (QoL).
This was a prospective longitudinal crossover study between August 2011 and June 2013. All patients were >18 years old, diagnosed with CRS based on guideline recommendations, failed initial medical therapy and elected ESS. While waiting for ESS, all patients received continued medical therapy. The preoperative waiting period outcomes (continued medical therapy) were compared to the postoperative outcomes. The primary outcome was change in disease-specific QoL (22-item Sinonasal Outcome Test [SNOT-22]). Secondary outcomes were change in endoscopic grading (Lund-Kennedy score), medication consumption, and work days missed in the preceding 90 days.
Thirty-one patients were enrolled. Mean baseline SNOT-22 score was 57.6. After a mean of 7.1 months of continued medical therapy, there was a worsening in SNOT-22 score (57.6 to 66.1; p = 0.006). After ESS, with a mean postoperative follow-up of 14.6 months, there was a significant improvement in SNOT-22 score (66.1 to 16.0; p < 0.001). There was also a significant improvement in endoscopic grading (p < 0.001) coupled with a reduction in both work days lost (p < 0.001) and medication consumption (p < 0.01).
Results from the study suggest that ESS is a more effective intervention compared to continued medical therapy for patients with refractory CRS who have severe reductions in their baseline disease-specific QoL.
对于难治性慢性鼻-鼻窦炎(CRS)患者,决定继续药物治疗还是推荐鼻内镜鼻窦手术(ESS)可能具有挑战性。本研究的目的是评估继续药物治疗与ESS对难治性CRS且基线疾病特异性生活质量(QoL)严重降低的患者的疗效。
这是一项2011年8月至2013年6月的前瞻性纵向交叉研究。所有患者年龄>18岁,根据指南推荐诊断为CRS,初始药物治疗失败并选择ESS。在等待ESS期间,所有患者接受继续药物治疗。将术前等待期结果(继续药物治疗)与术后结果进行比较。主要结局是疾病特异性QoL的变化(22项鼻鼻窦结局测试[SNOT-22])。次要结局包括内镜分级的变化(Lund-Kennedy评分)、药物消耗以及前90天内错过的工作日天数。
共纳入31例患者。平均基线SNOT-22评分为57.6。经过平均7.1个月的继续药物治疗后,SNOT-22评分恶化(从57.6至66.1;p = 0.006)。ESS后,平均术后随访14.6个月,SNOT-22评分显著改善(从66.1至16.0;p < 0.001)。内镜分级也有显著改善(p < 0.001),同时误工天数(p < 0.001)和药物消耗均减少(p < 0.01)。
研究结果表明,对于难治性CRS且基线疾病特异性QoL严重降低的患者,与继续药物治疗相比,ESS是一种更有效的干预措施。